Health & Research Goals
Recomp Stack
Stack de Recomposición
High-Performance Stack
Select a vial or the total
Primary Description
Semaglutide drives caloric deficit through GLP-1 activation. CJC-1295 + Ipamorelin preserve lean mass by maintaining growth hormone levels. Targets body recomposition: fat loss while preserving muscle.
Demonstrated Effects
- Combined synergistic effect
- Maximized research outputs
- Pre-verified protocol
Proposed Mechanisms of Action
Combined Mechanism
Semaglutide activates GLP-1 receptors in the hypothalamus (appetite suppression), GI tract (gastric emptying delay), and pancreas (glucose-dependent insulin secretion) — creating the caloric deficit required for fat loss. During aggressive weight loss, endogenous GH secretion is typically compromised by negative energy balance and elevated cortisol. CJC-1295 No-DAC restores GHRH pulsatility to maintain GH-driven protein synthesis and lipolysis. Ipamorelin amplifies the GH peak selectively without cortisol elevation, which would otherwise accelerate muscle catabolism during the diet phase. Result: fat loss via GLP-1 + muscle preservation via GH secretagogue support.
Stack Compounds
Research Evidence & Clinical Data
Research Profile
Semaglutide drives caloric deficit via GLP-1. CJC/Ipa preserves lean mass by maintaining growth hormone levels. Targets recomposition — fat loss while preserving muscle.
Safety Profile
Common Side Effects
- GLP-1 nausea, diarrhea, constipation — titrate semaglutide slowly (start 0.25mg/week)
- Thyroid C-cell tumor warning for semaglutide component
- Monitor IGF-1 (GH secretagogue component)
- Water retention possible (CJC/Ipamorelin)
- Hypoglycemia risk if combined with insulin or sulfonylureas
Contraindications
- History of MTC or MEN2
- Active pancreatitis
- Active malignancy (GH component)
- Pregnancy
Analytical Quality Assurance
Research Protocols
Dosing Protocols
Combined Research Protocol: Stack de Recomposición
Sub-QMonitoring & Risk Management
Compound Stack Monitoring
For stacks and blends, refer to the individual compound monographs for each included ingredient for specific monitoring guidelines.